Tamer DEMİR, FAtih ULAŞ, Özkaya Ülkü ÇELİKER

Role of interferon-alpha 2B and octreotide in prevention of experimentally induced corneal neovascularization in rats

Amaç: Bu çalışmanın amacı interferon-alfa 2b (IFN-$alpha$2b)'nin ve uzun etkili somatostatin analoğu olan oktreotidin, deneysel olarak uyarılan kornea neovaskülarizasyonu üzerine etkilerini araştırmaktı. Metod: Gümüş nitrat koterizasyon ile 30 ratın birer gözünde kimyasal keratit oluşturuldu. Denekler rastgele onarlı üç gruba ayrılarak bir gruba günde dört kez subkütan IFN-$alpha$2b (250.000 IU), diğer gruba oktreotid (1O$mu$g) infeksiyonu yapıldı. Geri kalan grup ise kontrol grubu olarak çalışmaya dahil edildi. Tüm deneklerin korneaları sekizinci günde biomikroskopik ve histopatolojik olarak elektron mikroskopu ile neovaskülarizasyonun önlenip önlenemediği konusunda değerlendirildi. Bulgu: Bu çalışmada kornea neovaskülarizasyonu ve histopatolojik skorlar hem IFN (p

Ratlarda deneysel olark indüklenen kornea neovaskülarizasyonun önlenmesinde interferon-alfa 2B ve oktreotidin rolü

Purpose: To investigate the effects of interferon-alpha2b (JFN-$alpha$2b) and octreotide, a long-acting analogue of somatostatin, on experimentally induced corneal neovascularization. Methods: Chemical keratitis was induced unilaterally in the eyes of 30 rats by silver nitrate cauterization. Ten of these animals received subcutaneous IFN-$alpha$2b (250,000 IU) four times every other day (interferon group) and ten rats were injected with octreotide (10 $$mu$g) (octreotide group). The remaining ten rats were used as controls. The corneas of all animals were biomicroscopically and histopathologically examined on day 8 by electron microscope to observe whether there was inhibition of neovascularization or not. Results: Corneal neovascularization and histopathological scores were lower in both the interferon group (p

PDF

___

1. Richard C, William W, Anthony PA. Ocular angiogenesis. In. Albert MD, Jacobiec AF (eds.): Principles and Practice of Ophthalmology Basic Sciences. Philadelphia: The Curtis Center: 1994. p.1100-1106.
2. Pegram M, Mitsuyasu RT. Immune modulation; interferons and interleukins. In. Rich RR, Fleisher TA, Schwartz BD (eds.): Clinical Immunol Principles and Pratice. Mosby: 1995. p. 2030-2045.
3. Mahoney J, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterisation of the rat cornea. Current Eye Res 1985; 4: 531-535.
4. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of VEGF and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002; 133: 70-77.
5. Yogesh C, Murthy KK, Escher EE. Mechanism of action of somatostatin. An overview of receptor function and studies of the molecular characterisation and purification of somatostatin receptor proteins. Metabolism 1990; 39: 63-69.
6. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002; 74: 553-559.
7. Green CJ. Animal Anaesthesia Laboratory. London: Oxford Press; 1982.
8. Granzyna M,.Niederkon K, Niederkon JY. Spontaneous corneal neovascularization in nude mice. Invest Ophthalmol Vis Sci 1993; 31: 222-230.
9. Steinmann LT, Koppler BH, Jennings CD. Corneal allograft rejection following immunization. Am J Ophthalmol 1988; 106: 575-578.
10. Kinoshita S, Manabe R. Chemical burns. In. Brightbill FS (ed): Corneal Surgery. St Louis: Mosby Year-Book: 1992. p. 316-317.
11. Nirankari US, Dandona L, Rodrigues MM. Laser photocoagulation experimental corneal stromal vascularization. Ophthalmol 1994; 100: 111-118.
12. Avery RL, Connor TB, Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Opht 1990; 108: 1474-1476.
13. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high risk corneal transplants. Ophthalmology 1989; 96: 1144-1150.
14. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 1994; 112: 1471-1475.
15. Park WC, Rho and Shin DH. Regression of experimental cornea vascularization with subconjunctival injection of interferon alpha-2a. Invest Opthal 1994; 35: 1351-1357.
16. Boye DB, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 28: 516-518.
17. Poliner SL, Tornabe EP, Michelson EP, Heitzman GJ. Interferon alpha 2-a for subfoveal neovascularization in age-related macular degeneration. Ophthalmol 1993; 9: 1417-1424.
18. Miller JW, Stinson WG, Folkman W. Regression of experimental iris neovascularization with systemic alpha interferon. Ophthalmol 1993; 100: 145-148.
19. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989; 16: 95- 115.
20. Tripathi RC, Raja SC, Tripathi BJ. Prospects for epidermal growth factor in the management of corneal disorders. Surv Ophthalmol 1990; 34: 457-459.
21. Leibowitz HM, Morello S, Stern M, Kupferman A. Effect of topically administered epidermal growth factor on corneal wound strength. Arch Ophthalmol 1990; 108: 734-737.
22. Baudoin C, Reygrobellet DF, Caruelle JP. Acidic fibroblast growth factor distribution in normal human eye and possible implications in ocular pathogenesis. Ophthalmic Res 1990; 22: 73-81.
23. Reygrobellet FD, Boudouin C, Negre F, Caruelle JP, Gastaud P. Acidic FGF and other growth factors in preretinal membranes from patients with diabetic retinopathy and proliferative vitreoretinopathy. Ophthalmic Res 1991; 23: 154-161.
24. Satoh T, Kan M, Masuko K, Obinata M. Characterisation of a new endothelial cell growth factor (f-ECGF) partially purified from the supernatant of human fibroblast cells. Biol Cell Jpn Soc 1989; 14: 731-740.
25. Robertson JE, Westra I, Woltering EA, Winthrop KL, Barrie R, O'Dorisio TM, Holmes D. Intravitreal injection of octreotide acetate. J Ocul Pharmacol Ther 1997; 13: 171-177.
26. Luo Q, Peyman GA, Conway MD, Woltering EA. Effect of a somatostatin analogue (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996; 15: 909-913.
27. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000; 23: 504-509.
28. Kurg AW, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 1996; 6: 381-384.
29. Günal Al, Işık A, Çeliker H, Eren O. Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart 1996; 76: 418-421.
30. Bartalena L, Marcocci C, Tanda L, Pinchera A. Management of thyroid eye disease. Eur J Nucl Med Mol Imaging. 2002; 29 Suppl 2: 458-65.